Please wait while we load the requested 10-K report or click the link below:
For Investors: Rebecca Peterson, (781) 609-6378
For Media: Jennifer Snyder, (781) 609-6166
PROVIDES FINANCIAL EXPECTATIONS FOR FISCAL 2011
|||Total revenues of $178.3 million for fiscal 2010.|
|||Record manufacturing and royalty revenues from RISPERDAL® CONSTA® of $146.0 million. Worldwide sales of RISPERDAL CONSTA by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. and JanssenCilag (Janssen) were approximately $1.5 billion in fiscal 2010, an 11.5 percent increase over sales of RISPERDAL CONSTA in fiscal 2009.|
|||Strong financial position, with cash and investments of $350.2 million.|
|||Significant recurring revenues from RISPERDAL CONSTA and strong cash balance enabled company to introduce two new proprietary technology platforms and advance six pipeline candidates.|
|||Received U.S. Food and Drug Administration (FDA) classification of the BYDUREON (exenatide for extended-release injectable suspension) complete response as a Class 2 resubmission and designation of a new Prescription Drug User Fee Act (PDUFA) action date of October 22, 2010.|
|||Disclosed BYDUREON royalty rate of 8% of net sales from the first 40 million units of BYDUREON sold in a particular calendar year and 5.5% of net sales from units sold beyond the first 40 million for that year. Alkermes will also receive a $7 million|
Page 1 of 9
The following information was filed by Alkermes Inc on Thursday, May 13, 2010 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Alkermes Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Alkermes Inc.